Aptamin®
DNA Aptamer
Since the SELEX (Systematic Evolution of Ligands by Exponential enrichment) of aptamer
excavation technology is developed by Larry Gold’s team at Colorado College in 1990, the first commercialized
aptamer was developed by Nexmos researchers.
Nexmos' Aptamer Technology
Therapeutics
- 1) CNS disease targeted Aptamer
- - Alzheimer’s Disease, Parkinson’s Disease
- 2) Wnt Signaling targeted Aptamer
- - Hair loss, Wound Healing
Drug Delivery System
- 1) Cell Penetrating Aptamer
- - BBB Penetrating Aptamer for CNS Drug
- - Skin Cell Penetrating Aptamer for Derma
- 2) Aptamer-Nanoparticle Complexation
- - Aptamer-Liposome Complex
- - Aptamer-Poloxamer Micell Complex
Diagnostics
- 1) In vitro : biomarker binding
- - Bladder Cancer
- - Dental Disease
- 2) Contrast agent
- - Alzheimer’s MRI Contrast Agent
ROS (Reactive Oxygen Species)Scavenger Boosting System
- - Skin Care
- - Neuro degeneration